EGFR mutant抗体—艾普蒂 新品

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using EGFR mutant mouse mAb against SPC-A-1 (1), A549 (2), HepG2 (3) and MCF-7 (4) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of HepG2 cells using EGFR mutant mouse mAb (green) and negative control (purple).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using EGFR mutant mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using EGFR mutant mouse mAb with DAB staining.    

  
  

Epidermal Growth Factor Receptor (EGFR) is a transmembrane tyrosine kinase receptor regulating cell proliferation, survival, and differentiation. Mutations in the *EGFR* gene, particularly exon 19 deletions and L858R substitutions, drive constitutive kinase activation, promoting oncogenesis in non-small cell lung cancer (NSCLC) and other malignancies. Targeting mutant EGFR has become a cornerstone of precision oncology.

EGFR mutant-specific antibodies are critical tools for both diagnostic and therapeutic applications. Therapeutically, monoclonal antibodies (e.g., cetuximab, panitumumab) bind EGFR’s extracellular domain to block ligand-induced signaling. However, these antibodies primarily target wild-type EGFR and show limited efficacy against tumors harboring kinase domain mutations. Tyrosine kinase inhibitors (TKIs), such as osimertinib, more directly inhibit mutant EGFR kinase activity and remain first-line therapies.

Diagnostically, mutation-selective antibodies (e.g., EGFR exon 19 deletion-specific clones) enable immunohistochemical detection of mutant EGFR in tumor samples, aiding rapid clinical decision-making where molecular testing is unavailable. Recent advancements include bispecific antibodies and antibody-drug conjugates designed to enhance tumor specificity and overcome TKI resistance mechanisms like T790M or C797S mutations.

Research continues to address challenges such as tumor heterogeneity, resistance, and on-target toxicity. The integration of mutant EGFR antibodies with next-generation sequencing and combination therapies underscores their evolving role in personalized cancer treatment.